Thoraco-Abdominal Chemo and Surgery for Peritoneal Carcinomatosis: Is It Safe and Effective?

This study delves into the safety and effectiveness of combining hyperthermic intraoperative thoraco-abdominal chemotherapy (HITAC) with cytoreductive surgery (CRS) in patients with peritoneal carcinomatosis (PC) who need diaphragm resection. Researchers compared HITAC to traditional intraperitoneal chemotherapy (HIPEC). Results show that HITAC is a viable option with similar safety profiles, and it might offer benefits for pleural progression. The key findings were no significant differences in adverse events, time to progression, or overall survival between the two approaches. Some factors, like age and specific types of cancer, influenced outcomes.